In 2021, Carlisle’s group at the University of Oxford demonstrated that encapsulation of poxvirus in an amphiphilic polymer shielded it from neutralizing antibodies, followed by targeted delivery of anti-MUC1 antibodies to MUC1-expressing tumor cells by conjugation of anti-MUC1 antibodies to the surface of the ampholymer [84]. This evidence concerns the gene MUC1 and neoplasm.